OClawVPS.com
Nicox
Edit

Nicox

http://www.nicox.com/
Last activity: 12.01.2026
Active
Categories: DeliveryDevelopmentDiagnosticsDrugEngineeringMedTechProductResearchScienceTechnology
Nicox is an international ophthalmic R&D company, aiming to build a diversified portfolio of therapeutic products addressing the needs of eyecare practitioners and patients around the world.

Our global growth strategy is focused on outstanding international collaborations and on our proprietary programs including those from our nitric oxide-donating research platform.

For more information please visit www.nicox.com
Mentions
98
Employees: 11-50
Phone: +51 912 163 823
Total raised: $3.42M
Founded date: 1996
Facebook
LinkedIn
Email

Investors 3

Funding Rounds 1

DateSeriesAmountInvestors
27.05.2025-$3.42M-

Mentions in press and media 98

DateTitleDescription
12.01.2026Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and P...TAIPEI, Jan. 12, 2026 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Samil Pharmaceuticals, Co., Ltd ("Samil&q...
29.09.2025Lupin Strengthens its Global Specialty Ophthalmology Business with Acquisition of VISUfarma from GHO CapitalLONDON, ROME and ZUG, Switzerland, Sept. 29, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN), today announced its wholly owned subsidiary, Nanomi B.V. ('Nanomi...
27.05.2025Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in JapanPress Release Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan Exclusive Japanese partner Kowa has received regulatory approval to initiate Phase 3 clinic...
27.05.2025Nicox annonce jusqu’à 3 millions d’euros de paiements d’étapes de la part de Kowa en 2025, alors que NCX 470 se prépare à entrer en essais cliniques de Phase 3 au JaponCommuniqué de presse Nicox annonce jusqu’à 3 millions d’euros de paiements d’étapes de la part de Kowa en 2025, alors que NCX 470 se prépare à entrer en essais cliniques de Phase 3 au Japon Kowa, le partenaire exclusif de Nicox au Japon, a ...
19.03.2025Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma TrialPress Release Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial Results expected in May 2025 Last patient in the U.S. in the ongoing NCX 470 Denali Phase 3 trial has also completed their last vis...
02.12.2024Nicox : Recrutement de patients achevé plus tôt que prévu en Chine dans l’étude clinique de phase 3 Denali sur NCX 470Communiqué de presse Nicox : Recrutement de patients achevé plus tôt que prévu en Chine dans l’étude clinique de phase 3 Denali sur NCX 470 Confirmation que les premiers résultats sont attendus au troisième trimestre 2025 NCX 470 a démontré...
02.12.2024Nicox’s Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than ExpectedPress Release Nicox’s Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected Confirms topline results expected to be reported Q3 2025 NCX 470 demonstrated robust efficacy and safety in topline results from first Phase...
19.11.2024Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 TrialPress Release Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 Trial An adaptive design is a useful clinical trial design tool which allowed identification of the optimal dose of NCX 470 in the Mon...
17.10.2024Nicox Provides Third Quarter 2024 update and First Half 2024 Financial ResultsPress Release Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results Topline results from the NCX 470 (bimatoprost grenod) Phase 3 Denali clinical trial expected in Q3 2025Cash of €19.7 million on September 30, 2024,...
23.09.2024Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option AgreementPress Release Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement Option entitles Glaukos to exclusive global license agreements on pre-agreed terms including upfront and milestone payments plus royaltie...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In